BillionToOne (BLLN) IPO deck
BillionToOne develops advanced prenatal and oncology diagnostics using its proprietary single-molecule sequencing technology to enable ultra-sensitive, non-invasive disease detection and personalized care.
BillionToOne develops advanced prenatal and oncology diagnostics using its proprietary single-molecule sequencing technology to enable ultra-sensitive, non-invasive disease detection and personalized care.
%20IPO%20deck){kind=link}